{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:10:47Z","timestamp":1773425447825,"version":"3.50.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2019.00067","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T05:08:26Z","timestamp":1553576906000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors"],"prefix":"10.3389","volume":"9","author":[{"given":"Draginja","family":"Radosevic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Sencanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Perovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevena","family":"Veljkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Prljic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veljko","family":"Veljkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Mantlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalya","family":"Bukreyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slobodan","family":"Paessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanja","family":"Glisic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"B1","first-page":"101","article-title":"Inhibition effect of alpha-lipoic acid on the propagation of influenza a virus in MDCK cells","volume":"32","author":"Bai","year":"2012","journal-title":"Pak. Vet. J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e55271","DOI":"10.1371\/journal.pone.0055271","article-title":"Inhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assay","volume":"8","author":"Balgi","year":"2013","journal-title":"PLoS ONE"},{"key":"B3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/9781118636817.ch26","article-title":"The control of influenza and cost effectiveness of interventions","volume-title":"Influenza Textbook","author":"Bridges","year":"2013"},{"key":"B4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nature08722","article-title":"Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers","volume":"463","author":"Cady","year":"2010","journal-title":"Nature"},{"key":"B5","first-page":"44","article-title":"High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005-06 influenza season. MMWR Morb","volume":"55","year":"2006","journal-title":"Mortal. Wkly"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e48335","DOI":"10.1371\/journal.pone.0048335","article-title":"Methamphetamine reduces human influenza A virus replication","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS ONE"},{"key":"B7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJM198209023071002","article-title":"A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection","volume":"307","author":"Dolin","year":"1982","journal-title":"N. Engl. J. Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0119115","DOI":"10.1371\/journal.pone.0119115","article-title":"Adamantane-resistant influenza A viruses in the World (1902\u20132013): frequency and distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS ONE"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1021\/ci800037t","article-title":"Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in molecular interaction fields","volume":"48","author":"Duran","year":"2008","journal-title":"J. Chem. Inf. Model"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1021\/ci900228x","article-title":"Suitability of GRIND-based principal properties for the description of molecular similarity and ligand-based virtual screening","volume":"49","author":"Duran","year":"2009","journal-title":"J. Chem. Inf. Model"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/mds.26102","article-title":"The medical treatment of Parkinson disease from James Parkinson to George Cotzias","volume":"30","author":"Fahn","year":"2015","journal-title":"Mov. Disord"},{"key":"B12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijms19082419","article-title":"Vitamin D and influenza-prevention or therapy?","volume":"16","author":"Gruber-Bzura","year":"2018","journal-title":"Int. J. Mol. Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/infdis\/jiq012","article-title":"Emerging influenza antiviral resistance threats","volume":"203","author":"Hayden","year":"2011","journal-title":"J. Infect. Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/pro.2158","article-title":"Structural basis for proton conduction and inhibition by the influenza M2 protein","volume":"21","author":"Hong","year":"2012","journal-title":"Protein Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/j.1468-1331.2006.01547.x","article-title":"European Federation of Neurological Societies; Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease","volume":"13","author":"Horstink","year":"2006","journal-title":"Eur. J. Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2807\/1560-7917.ES.2017.22.47.17-00731","article-title":"Detection of adamantane-sensitive influenza A(H3N2) viruses in Australia, 2017: a cause for hope?","volume":"22","author":"Hurt","year":"2017","journal-title":"Euro Surveill"},{"key":"B17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.antiviral.2016.06.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014\u20132015","volume":"132","author":"Hurt","year":"2016","journal-title":"Antiviral Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.antiviral.2009.03.003","article-title":"Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa","volume":"83","author":"Hurt","year":"2009","journal-title":"Antiviral Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1056\/NEJMc1111078","article-title":"Community transmission of oseltamivir-resistant A (H1N1) pdm09 influenza","volume":"365","author":"Hurt","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccm.2016.11.008","article-title":"Antiviral treatments","volume":"38","author":"Ison","year":"2017","journal-title":"Clin. Chest Med"},{"key":"B21","first-page":"1071","article-title":"Cycrimine, a new drug in the treatment of Parkinson's disease and Parkinsonism","volume":"44","author":"Kafer","year":"1957","journal-title":"Prensa Med. Argent"},{"key":"B22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/0092-8674(85)90211-9","article-title":"Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface","volume":"40","author":"Lamb","year":"1985","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1124\/mol.116.105346","article-title":"Pharmacological characterization of the spectrum of antiviral activity and genetic barrier to drug resistance of M2-S31N channel blockers","volume":"90","author":"Ma","year":"2016","journal-title":"Mol. Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1128\/AAC.44.4.859-866.2000","article-title":"Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon","volume":"44","author":"Markland","year":"2000","journal-title":"Antimicrob. Agents Chemother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","article-title":"Drug repurposing for viral infectious diseases: how far are we?","volume":"26","author":"Mercorelli","year":"2018","journal-title":"Trends Microbiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity","volume":"16","author":"Morris","year":"2009","journal-title":"J. Comput. Chem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1534-5807(03)00190-4","article-title":"Influenza B virus BM2 protein has ion channel activity that conducts protons across membranes","volume":"5","author":"Mould","year":"2003","journal-title":"Dev. Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2741\/4627","article-title":"Ibuprofen as a template molecule for drug design against Ebola virus","volume":"23","author":"Paessler","year":"2018","journal-title":"Front. Biosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1021\/jm000941m","article-title":"Grid-Independent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors","volume":"43","author":"Pastor","year":"2000","journal-title":"Med. Chem"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1073\/pnas.94.10.5000","article-title":"The active oligomeric state of the minimalistic influenza virus M2 ion channel is a tetramer","volume":"94","author":"Sakaguchi","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B31","first-page":"57","article-title":"Python: a programming language for software integration and development","volume":"1","author":"Sanner","year":"1999","journal-title":"J. Mol. Graphics Mod"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.2174\/1381612821666151002113426","article-title":"Natural products as promising therapeutics for treatment of influenza disease","volume":"21","author":"Sencanski","year":"2015","journal-title":"Curr. Pharm. Des"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/molbev\/msm103","article-title":"The genesis and spread of reassortment human influenza A\/H3N2 viruses conferring adamantane resistance","volume":"24","author":"Simonsen","year":"2007","journal-title":"Mol. Biol. Evol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00894-012-1667-x","article-title":"Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters","volume":"19","author":"Stewart","year":"2013","journal-title":"J. Mol. Mod."},{"key":"B35","unstructured":"StewartJ. J. P.\n          Colorado Springs, COMOPAC2016. Stewart Computational Chemistry2016"},{"key":"B36","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/nm.3595","article-title":"Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks","volume":"20","author":"Strittmatter","year":"2014","journal-title":"Nat. Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1128\/JVI.76.3.1391-1399.2002","article-title":"Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture","volume":"76","author":"Takeda","year":"2002","journal-title":"J. Virol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1021\/ci700078n","article-title":"Novel virtual screening protocol based on the combined use of molecular modeling and electron-ion interaction potential techniques to design HIV-1 integrase inhibitors","volume":"47","author":"Tintori","year":"2007","journal-title":"J. Chem. Inf. Model"},{"key":"B39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.antiviral.2017.11.004","article-title":"Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens","volume":"149","author":"Tong","year":"2018","journal-title":"Antiviral Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1517\/17460441.2012.638280","article-title":"The role of long-range intermolecular interactions in discovery of new drugs","volume":"6","author":"Veljkovic","year":"2011","journal-title":"Exp. Opin. Drug Disc"},{"key":"B42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2174\/138920101405131111105301","article-title":"Simple and general criterion for \u201cin silico\u201d screening of candidate HIV drugs","volume":"14","author":"Veljkovic","year":"2013","journal-title":"Curr. Pharm. Biotechnol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.12688\/f1000research.6436.1","article-title":"In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease","volume":"4","author":"Veljkovic","year":"","journal-title":"F1000Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.12688\/f1000research.6110.1","article-title":"Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection","volume":"4","author":"Veljkovic","year":"","journal-title":"F1000Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/fvl.15.95","article-title":"M2 as a target to combat influenza drug resistance: what does the evidence say?","volume":"11","author":"Wang","year":"2016","journal-title":"Future Virol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1073\/pnas.1216526110","article-title":"Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus","volume":"110","author":"Wang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B47","unstructured":"Factsheet; March2018"},{"key":"B48","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature18615","article-title":"Toremifene interacts with and destabilizes the Ebola virus glycoprotein","volume":"535","author":"Zhao","year":"2016","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bph.13895","article-title":"Drug repurposing screens and synergistic drug-combinations for infectious diseases","volume":"175","author":"Zheng","year":"2018","journal-title":"Br. J. Pharmacol"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2019.00067\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T05:08:37Z","timestamp":1553576917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2019.00067\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":50,"alternative-id":["10.3389\/fcimb.2019.00067"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2019.00067","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"article-number":"67"}}